Rhabdomyolysis Associated with Cerivastatin: Six Cases within 3 Months at One Hospital
Authors:
- 1 June 2002
- journal article
- case report
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 22 (6) , 771-774
Abstract
Rhabdomyolysis is an uncommon complication associated with 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors. We observed six cases of cerivastatin‐associated rhabdomyolysis: two patients developed acute renal failure requiring hemodialysis, and one patient died. Four of the patients had impaired renal function, and five were prescribed drugs with the potential to interact with cerivastatin. Also, five of the six patients presented with symptoms of rhabdomyolysis 3–4 weeks after starting cerivastatin therapy.Keywords
This publication has 8 references indexed in Scilit:
- Cerivastatin and Reports of Fatal RhabdomyolysisNew England Journal of Medicine, 2002
- FDA Adverse Event Reports on Statin-Associated RhabdomyolysisAnnals of Pharmacotherapy, 2002
- Cerivastatin and Gemfibrozil—Associated RhabdomyolysisAnnals of Pharmacotherapy, 2001
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Cerivastatin-Induced RhabdomyolysisAnnals of Internal Medicine, 2000
- Concomitant use of cytochrome P450 3A4 inhibitors and simvastatinThe American Journal of Cardiology, 1999
- Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapyThe American Journal of Cardiology, 1999
- CerivastatinDrugs, 1998